Medical Communications
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023 Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
September 29, 2023 Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia
Kura Oncology shares preclinical data for NSCLC treatment
September 29, 2023 Medical Communications Kura Oncology, NSCLC, Oncology, oncology
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023 Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
CDC Advisory Committee recommends Pfizer’s RSV vaccine
September 25, 2023 Medical Communications Abrysvo, Immunology, Pfizer, RSV
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023 Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis
September 22, 2023 Medical Communications FDA, Haematology, Nexcella, amyloidosis
Novo Nordisk partners with UNICEF to prevent global childhood obesity
September 21, 2023 Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023 Medical Communications European Commission, Oncology, Orserdu, breast cancer
Pharmanovia acquires CNS portfolio from Sanofi
September 20, 2023 Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition
EC approves Pfizer’s Litfulo for adolescents and adults with alopecia
September 19, 2023 Medical Communications Dermatology, EC, Litfulo, alopecia
GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia
September 18, 2023 Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis
GSK and Save the Children extend partnership for unvaccinated children
September 15, 2023 Medical Communications GSK, Immunology, childhood vaccination, vaccines
Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA
September 14, 2023 Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom
FDA approves LimFlow system for patients with CLTI
September 13, 2023 Medical Communications CLTI, Devices, FDA, LimFlow
Latest content
